Stocks Health care AURX
OTC · Health careNuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. brought in $5.2M of revenue over the twelve months to June 30, 2026, up 166.6% from a year earlier. It posted a net loss of $2M. In fiscal 2025 capital spending exceeded operating cash flow by $1.1M. At June 30, 2026 it held $449.3K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch AURX in 60 secondsWhat Nuo Therapeutics, Inc. does
Nuo Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker AURX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.3M | -$2.5M | -$0.05 | -$1.1M |
| 2024 | $1.4M | -$2.3M | -$0.05 | -$2.4M |
| 2023 | $608.5K | -$3.2M | -$0.08 | -$3.2M |
| 2022 | $112.3K | -$3.2M | -$0.08 | -$3.8M |
| 2021 | $0 | -$90.7K | -$0.03 | -$120K |
| 2021 | $0 | -$90.9K | $0.27 | -$53.8K |
Full financial statements: income, balance sheet and cash flow
Where AURX ranks in Health care
Latest SEC filings
What Nuo Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 17, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 153% to $1.8M versus the same quarter last year; diluted EPS -$0.01 versus -$0.01.
- June 3, 2026Activist stake changed SCHEDULE 13D/A
- June 3, 2026
- May 14, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 169% to $1.3M versus the same quarter last year; diluted EPS -$0.01 versus -$0.02.
- March 30, 2026Annual report 10-K · period to December 31, 2025Revenue rose 143% to $3.3M versus the prior year; diluted EPS -$0.05 versus -$0.05.
- February 12, 2026Passive stake changed SCHEDULE 13G/A
- January 26, 2026Activist stake changed SCHEDULE 13D/A
- January 26, 2026
Insider trades
What the people running Nuo Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $9.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 28, 2026 | Jorden David EmersonCEO/CFO, Director | Bought | 7,984 | $8.7K |
| August 27, 2026 | Jorden David EmersonCEO/CFO, Director | Bought | 789 | $844.2 |
| June 30, 2026 | Winzer C EricDirector | Exercised options | 40,000 | $40K |
| June 30, 2026 | Winzer C EricDirector | Shares withheld for tax | 39,604 | $40K |
| June 30, 2026 | Pittman Scott M.Director, 10% owner | Exercised options | 40,000 | $40K |
| June 30, 2026 | Pittman Scott M.Director, 10% owner | Shares withheld for tax | 39,604 | $40K |
| June 30, 2026 | Jorden David EmersonCEO/CFO, Director | Exercised options | 162,500 | $162.5K |
| June 30, 2026 | Jorden David EmersonCEO/CFO, Director | Shares withheld for tax | 160,892 | $162.5K |
| June 5, 2026 | Jorden David EmersonCEO/CFO, Director | Received as pay | 13,245 | $14.5K |
Who owns AURX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Pittman Scott M.13D, may seek influence | 11.6% | June 3, 2026 |
| Jacobs Paul Anthony13G, passive | 6.6% | February 12, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 7,643,446 shares in total, about $9.6M at the last price.
| Holder | Shares |
|---|---|
| Pittman Scott M.Director, 10% owner | 5,400,396 |
| Jorden David EmersonCEO/CFO, Director | 2,070,000 |
| Winzer C EricDirector | 173,050 |
Questions about AURX
What does Nuo Therapeutics, Inc. do?
Nuo Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker AURX.
Is Nuo Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2M on revenue of $5.2M.
How much revenue does Nuo Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Nuo Therapeutics, Inc. reported revenue of $5.2M. That is 166.6% more than a year earlier.
When did Nuo Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade (amended) from August 31, 2026.
Similar companies
Compare AURX with
Follow AURX
Get an email when Nuo Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AURX: get an email when it filesWhere the numbers come from
Financial figures are the values Nuo Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.